Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Bayer AG - Leverkusen, Germany-based pharmaceutical and chemical maker - Joins forces with Acuitas Therapeutics Inc, a biotechnology company that develops lipid nanoparticle delivery systems for molecular therapeutics. Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver.
‘Adding Acuitas’ clinically-validated and scalable LNP technology to our genomic medicine toolbox is another important step to advance our leadership in the field of cell and gene therapies,’ says Jost Reinhardt, head of cell and gene therapy in the pharmaceuticals division at Bayer.
Current stock price: €52.50
12-month change: down 21%
Copyright 2023 Alliance News Ltd. All Rights Reserved.